Last reviewed · How we verify
Placebo matching gepotidacin
Placebo matching gepotidacin is a Bacterial topoisomerase inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Uncomplicated urogenital gonorrhea, Acute bacterial skin and skin structure infections.
Gepotidacin is a novel bacterial topoisomerase inhibitor that prevents bacterial DNA replication and transcription by targeting DNA gyrase and topoisomerase IV.
Gepotidacin is a novel bacterial topoisomerase inhibitor that prevents bacterial DNA replication and transcription by targeting DNA gyrase and topoisomerase IV. Used for Uncomplicated urogenital gonorrhea, Acute bacterial skin and skin structure infections.
At a glance
| Generic name | Placebo matching gepotidacin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Bacterial topoisomerase inhibitor |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Gepotidacin belongs to a new class of antibiotics called triazaacenaphthylenes that inhibit bacterial topoisomerases, enzymes essential for DNA unwinding and replication. By blocking these enzymes, gepotidacin prevents bacteria from replicating their DNA and transcribing genes, leading to bacterial cell death. This mechanism differs from fluoroquinolones and provides activity against resistant gram-negative and gram-positive pathogens.
Approved indications
- Uncomplicated urogenital gonorrhea
- Acute bacterial skin and skin structure infections
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
- Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI) (PHASE3)
- Drug-drug Interaction Study of Gepotidacin (PHASE1)
- Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects (PHASE1)
- A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers (PHASE1)
- This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching gepotidacin CI brief — competitive landscape report
- Placebo matching gepotidacin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo matching gepotidacin
What is Placebo matching gepotidacin?
How does Placebo matching gepotidacin work?
What is Placebo matching gepotidacin used for?
Who makes Placebo matching gepotidacin?
What drug class is Placebo matching gepotidacin in?
What development phase is Placebo matching gepotidacin in?
What are the side effects of Placebo matching gepotidacin?
What does Placebo matching gepotidacin target?
Related
- Drug class: All Bacterial topoisomerase inhibitor drugs
- Target: All drugs targeting DNA gyrase and topoisomerase IV
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Uncomplicated urogenital gonorrhea
- Indication: Drugs for Acute bacterial skin and skin structure infections
- Compare: Placebo matching gepotidacin vs similar drugs
- Pricing: Placebo matching gepotidacin cost, discount & access